Etidronate disodium in postmenopausal osteoporosis

Robert P. Heaney, Paul D. Saville

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10%, and effective retained dose was approximately 1.6 mg/kg/day. Patient acceptance was excellent, and there were no detectable clinical or biochemical untoward effects of treatment. Serum phosphorus was elevated an average of 1.1 mg/100 ml, and serum calcium, 0.4 mg/100 ml. EHDP reduced bone resorption by about 50% and depressed bone mineralization by almost as much. Both the total miscible calcium pool and its component compartments were smaller on EHDP, presumably because of a combination of interference with bone mineral reactivity and the decrease in mineralization rate. Urine calcium was increased by a small, but highly significant, amount, and gastrointestinal calcium absorption was also significantly increased. Calcium balance shifted slightly but significantly in the positive direction. The magnitude of these changes correlated with the urinary level of EHDP.

Original languageEnglish
Pages (from-to)593-604
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume20
Issue number5
StatePublished - Nov 1976

Fingerprint

Etidronic Acid
Postmenopausal Osteoporosis
Calcium
Physiologic Calcification
Bone Resorption
Serum
Phosphorus
Minerals
Urine
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Heaney, R. P., & Saville, P. D. (1976). Etidronate disodium in postmenopausal osteoporosis. Clinical Pharmacology and Therapeutics, 20(5), 593-604.

Etidronate disodium in postmenopausal osteoporosis. / Heaney, Robert P.; Saville, Paul D.

In: Clinical Pharmacology and Therapeutics, Vol. 20, No. 5, 11.1976, p. 593-604.

Research output: Contribution to journalArticle

Heaney, RP & Saville, PD 1976, 'Etidronate disodium in postmenopausal osteoporosis', Clinical Pharmacology and Therapeutics, vol. 20, no. 5, pp. 593-604.
Heaney, Robert P. ; Saville, Paul D. / Etidronate disodium in postmenopausal osteoporosis. In: Clinical Pharmacology and Therapeutics. 1976 ; Vol. 20, No. 5. pp. 593-604.
@article{31008bc0882644368996f60bbb0bf647,
title = "Etidronate disodium in postmenopausal osteoporosis",
abstract = "Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10{\%}, and effective retained dose was approximately 1.6 mg/kg/day. Patient acceptance was excellent, and there were no detectable clinical or biochemical untoward effects of treatment. Serum phosphorus was elevated an average of 1.1 mg/100 ml, and serum calcium, 0.4 mg/100 ml. EHDP reduced bone resorption by about 50{\%} and depressed bone mineralization by almost as much. Both the total miscible calcium pool and its component compartments were smaller on EHDP, presumably because of a combination of interference with bone mineral reactivity and the decrease in mineralization rate. Urine calcium was increased by a small, but highly significant, amount, and gastrointestinal calcium absorption was also significantly increased. Calcium balance shifted slightly but significantly in the positive direction. The magnitude of these changes correlated with the urinary level of EHDP.",
author = "Heaney, {Robert P.} and Saville, {Paul D.}",
year = "1976",
month = "11",
language = "English",
volume = "20",
pages = "593--604",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Etidronate disodium in postmenopausal osteoporosis

AU - Heaney, Robert P.

AU - Saville, Paul D.

PY - 1976/11

Y1 - 1976/11

N2 - Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10%, and effective retained dose was approximately 1.6 mg/kg/day. Patient acceptance was excellent, and there were no detectable clinical or biochemical untoward effects of treatment. Serum phosphorus was elevated an average of 1.1 mg/100 ml, and serum calcium, 0.4 mg/100 ml. EHDP reduced bone resorption by about 50% and depressed bone mineralization by almost as much. Both the total miscible calcium pool and its component compartments were smaller on EHDP, presumably because of a combination of interference with bone mineral reactivity and the decrease in mineralization rate. Urine calcium was increased by a small, but highly significant, amount, and gastrointestinal calcium absorption was also significantly increased. Calcium balance shifted slightly but significantly in the positive direction. The magnitude of these changes correlated with the urinary level of EHDP.

AB - Calcium-balance, calcium-kinetic, and physiologic observations were made in 10 osteoporotic patients treated for 6 to 12 mo with disodium etidronate (EHDP) in oral doses of 20 mg/kg/day. Absorption of EHDP averaged 10%, and effective retained dose was approximately 1.6 mg/kg/day. Patient acceptance was excellent, and there were no detectable clinical or biochemical untoward effects of treatment. Serum phosphorus was elevated an average of 1.1 mg/100 ml, and serum calcium, 0.4 mg/100 ml. EHDP reduced bone resorption by about 50% and depressed bone mineralization by almost as much. Both the total miscible calcium pool and its component compartments were smaller on EHDP, presumably because of a combination of interference with bone mineral reactivity and the decrease in mineralization rate. Urine calcium was increased by a small, but highly significant, amount, and gastrointestinal calcium absorption was also significantly increased. Calcium balance shifted slightly but significantly in the positive direction. The magnitude of these changes correlated with the urinary level of EHDP.

UR - http://www.scopus.com/inward/record.url?scp=0017094012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017094012&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 593

EP - 604

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -